Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

BioCryst Pharmaceuticals Operating Income 2010-2025 | BCRX

BioCryst Pharmaceuticals operating income from 2010 to 2025. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
  
BioCryst Pharmaceuticals Annual Operating Income
(Millions of US $)
2024 $-3
2023 $-104
2022 $-148
2021 $-178
2020 $-175
2019 $-99
2018 $-94
2017 $-57
2016 $-49
2015 $-39
2014 $-46
2013 $-31
2012 $-34
2011 $-50
2010 $-34
2009 $-14
BioCryst Pharmaceuticals Quarterly Operating Income
(Millions of US $)
2025-03-31 $21
2024-12-31 $-5
2024-09-30 $8
2024-06-30 $9
2024-03-31 $-14
2023-12-31 $-43
2023-09-30 $-12
2023-06-30 $-21
2023-03-31 $-28
2022-12-31 $-46
2022-09-30 $-17
2022-06-30 $-35
2022-03-31 $-50
2021-12-31 $-52
2021-09-30 $-45
2021-06-30 $-30
2021-03-31 $-51
2020-12-31 $-52
2020-09-30 $-43
2020-06-30 $-39
2020-03-31 $-41
2019-12-31 $0
2019-09-30 $-35
2019-06-30 $-35
2019-03-31 $-29
2018-12-31 $-25
2018-09-30 $-28
2018-06-30 $-18
2018-03-31 $-22
2017-12-31 $-18
2017-09-30 $-13
2017-06-30 $-16
2017-03-31 $-11
2016-12-31 $-8
2016-09-30 $-9
2016-06-30 $-12
2016-03-31 $-19
2015-12-31 $-17
2015-09-30 $-13
2015-06-30 $5
2015-03-31 $-14
2014-12-31 $-15
2014-09-30 $-12
2014-06-30 $-12
2014-03-31 $-7
2013-12-31 $-6
2013-09-30 $-7
2013-06-30 $-12
2013-03-31 $-5
2012-12-31 $-11
2012-09-30 $-8
2012-06-30 $-10
2012-03-31 $-5
2011-12-31 $-11
2011-09-30 $-13
2011-06-30 $-14
2011-03-31 $-11
2010-12-31 $-10
2010-09-30 $-11
2010-06-30 $-10
2010-03-31 $-3
2009-12-31 $15
2009-09-30 $-11
2009-06-30 $-9
2009-03-31 $-9
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $2.310B $0.451B
BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $85.303B 32.00
Zoetis (ZTS) United States $75.058B 28.00
Daiichi Sankyo, - (DSNKY) Japan $49.349B 25.11
Takeda Pharmaceutical (TAK) Japan $47.824B 9.51
Sandoz Group AG (SDZNY) Switzerland $22.858B 0.00
Merck (MKKGY) Germany $17.228B 12.62
United Therapeutics (UTHR) United States $14.613B 12.93
Summit Therapeutics (SMMT) United States $14.527B 0.00
Shionogi (SGIOY) Japan $14.292B 14.32
Neurocrine Biosciences (NBIX) United States $12.323B 42.21
IPSEN (IPSEY) France $10.209B 0.00
Orion OYJ (ORINY) Finland $9.913B 26.81
Corcept Therapeutics (CORT) United States $7.421B 60.33
Stevanato Group S.p.A (STVN) Italy $6.772B 41.41
Madrigal Pharmaceuticals (MDGL) United States $6.202B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.153B 0.00
Grifols, S.A (GRFS) Spain $5.810B 0.00
Ionis Pharmaceuticals (IONS) United States $5.588B 0.00
Ono Pharmaceutical (OPHLF) Japan $4.875B 14.83
Soleno Therapeutics (SLNO) United States $3.882B 0.00
Catalyst Pharmaceuticals (CPRX) United States $3.085B 10.81
Crinetics Pharmaceuticals (CRNX) United States $3.008B 0.00
Hypermarcas (HYPMY) Brazil $2.882B 18.96
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.260B 12.22
NewAmsterdam Pharma (NAMS) Netherlands $2.177B 0.00
Recursion Pharmaceuticals (RXRX) United States $1.996B 0.00
Indivior (INDV) United States $1.885B 7.99
Centessa Pharmaceuticals (CNTA) United Kingdom $1.673B 0.00
Dyne Therapeutics (DYN) United States $1.524B 0.00
Evotec AG (EVO) Germany $1.456B 0.00
Guardian Pharmacy Services (GRDN) United States $1.361B 0.00
ARS Pharmaceuticals (SPRY) United States $1.357B 0.00
Ocular Therapeutix (OCUL) United States $1.335B 0.00
Enliven Therapeutics (ELVN) United States $1.094B 0.00
Harrow (HROW) United States $1.083B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.079B 21.59
Akebia Therapeutics (AKBA) United States $0.956B 0.00
Collegium Pharmaceutical (COLL) United States $0.945B 5.10
Avadel Pharmaceuticals (AVDL) Ireland $0.901B 0.00
Ardelyx (ARDX) United States $0.883B 0.00
Cronos Group (CRON) Canada $0.744B 0.00
Xeris Biopharma Holdings (XERS) United States $0.693B 0.00
KalVista Pharmaceuticals (KALV) United States $0.673B 0.00
Xencor (XNCR) United States $0.648B 0.00
AleAnna (ANNA) United States $0.630B 0.00
Elite Pharmaceuticals (ELTP) United States $0.598B 0.00
USANA Health Sciences (USNA) United States $0.554B 12.04
Relay Therapeutics (RLAY) United States $0.554B 0.00
Theravance Biopharma (TBPH) United States $0.551B 0.00
Regulus Therapeutics (RGLS) United States $0.550B 0.00
Bioventus (BVS) United States $0.536B 13.60
Zevra Therapeutics (ZVRA) United States $0.489B 0.00
Tourmaline Bio (TRML) United States $0.481B 0.00
Verve Therapeutics (VERV) United States $0.472B 0.00
Altimmune (ALT) United States $0.445B 0.00
Siga Technologies (SIGA) United States $0.439B 9.18
Amylyx Pharmaceuticals (AMLX) United States $0.439B 0.00
Oruka Therapeutics (ORKA) United States $0.437B 0.00
Savara (SVRA) United States $0.430B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.367B 9.92
Organogenesis (ORGO) United States $0.363B 0.00
Aquestive Therapeutics (AQST) United States $0.339B 0.00
Liminatus Pharma (LIMN) United States $0.331B 0.00
Heron Therapeutics (HRTX) United States $0.311B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.285B 0.00
Nature's Sunshine Products (NATR) United States $0.264B 24.42
MediWound (MDWD) Israel $0.235B 0.00
ProKidney (PROK) United States $0.231B 0.00
Esperion Therapeutics (ESPR) United States $0.222B 0.00
Nanobiotix S.A (NBTX) France $0.214B 0.00
Lyell Immunopharma (LYEL) United States $0.199B 0.00
4D Molecular Therapeutics (FDMT) United States $0.177B 0.00
Aclaris Therapeutics (ACRS) United States $0.174B 0.00
Journey Medical (DERM) United States $0.174B 0.00
OmniAb (OABI) United States $0.171B 0.00
Profound Medical (PROF) Canada $0.166B 0.00
Larimar Therapeutics (LRMR) United States $0.157B 0.00
Avita Medical (RCEL) United States $0.157B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.152B 0.00
Aldeyra Therapeutics (ALDX) United States $0.148B 0.00
Inhibikase Therapeutics (IKT) United States $0.147B 0.00
Wellgistics Health (WGRX) United States $0.141B 0.00
Nektar Therapeutics (NKTR) United States $0.139B 0.00
Achieve Life Sciences (ACHV) Canada $0.133B 0.00
Protara Therapeutics (TARA) United States $0.124B 0.00
Innate Pharma SA (IPHYF) France $0.122B 0.00
Cardiol Therapeutics (CRDL) Canada $0.120B 0.00
Korro Bio (KRRO) United States $0.112B 0.00
Cassava Sciences (SAVA) United States $0.104B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.104B 0.00
Inotiv (NOTV) United States $0.103B 0.00
Lexeo Therapeutics (LXEO) United States $0.103B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.097B 0.00
OptiNose (OPTN) United States $0.097B 0.00
Fractyl Health (GUTS) United States $0.096B 0.00
Unicycive Therapeutics (UNCY) United States $0.093B 0.00
VAXART, INC (VXRT) United States $0.092B 0.00
Nutriband (NTRB) United States $0.091B 0.00
Champions Oncology (CSBR) United States $0.088B 14.50
Arch Biopartners (ACHFF) Canada $0.087B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.083B 61.44
Galectin Therapeutics (GALT) United States $0.081B 0.00
Pyxis Oncology (PYXS) United States $0.079B 0.00
ESSA Pharma (EPIX) Canada $0.076B 0.00
Surrozen (SRZN) United States $0.071B 0.00
Dominari Holdings (DOMH) United States $0.071B 0.00
Vivani Medical (VANI) United States $0.066B 0.00
Assertio Holdings (ASRT) United States $0.064B 0.00
Metagenomi (MGX) United States $0.064B 0.00
Telomir Pharmaceuticals (TELO) United States $0.063B 0.00
Gain Therapeutics (GANX) United States $0.060B 0.00
Allergy Therapeutics (AGYTF) United Kingdom $0.059B 0.00
Prelude Therapeutics (PRLD) United States $0.056B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.055B 0.00
Context Therapeutics (CNTX) United States $0.052B 0.00
NRx Pharmaceuticals (NRXP) United States $0.051B 0.00
Century Therapeutics (IPSC) United States $0.049B 0.00
PMV Pharmaceuticals (PMVP) United States $0.048B 0.00
Avalo Therapeutics (AVTX) United States $0.047B 0.00
Mural Oncology (MURA) Ireland $0.045B 0.00
Rafael Holdings (RFL) United States $0.040B 0.00
ElectroCore (ECOR) United States $0.040B 0.00
Acrivon Therapeutics (ACRV) United States $0.039B 0.00
Iterum Therapeutics (ITRM) Ireland $0.038B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.038B 0.00
Karyopharm Therapeutics (KPTI) United States $0.038B 0.00
SCYNEXIS (SCYX) United States $0.037B 0.00
FibroGen (FGEN) United States $0.031B 0.00
PolyPid (PYPD) Israel $0.030B 0.00
Lyra Therapeutics (LYRA) United States $0.030B 0.00
Jupiter Neurosciences (JUNS) United States $0.027B 0.00
Tempest Therapeutics (TPST) United States $0.025B 0.00
Relmada Therapeutics (RLMD) United States $0.024B 0.00
CASI Pharmaceuticals (CASI) China $0.024B 0.00
Enlivex Therapeutics (ENLV) Israel $0.022B 0.00
Natural Alternatives (NAII) United States $0.021B 0.00
China SXT Pharmaceuticals (SXTC) China $0.021B 0.00
BioVie (BIVI) United States $0.020B 0.00
Mannatech (MTEX) United States $0.020B 0.00
DURECT (DRRX) United States $0.018B 0.00
Lipocine (LPCN) United States $0.017B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.017B 0.00
ProPhase Labs (PRPH) United States $0.016B 0.00
BioLineRx (BLRX) Israel $0.016B 0.00
VYNE Therapeutics (VYNE) United States $0.015B 0.00
Vivos Therapeutics (VVOS) United States $0.014B 0.00
GlycoMimetics (GLYC) United States $0.014B 0.00
Ainos (AIMD) United States $0.014B 0.00
Cosmos Health (COSM) United States $0.013B 0.00
TherapeuticsMD (TXMD) United States $0.013B 0.00
Minerva Neurosciences (NERV) United States $0.013B 2.26
Scienture Holdings (SCNX) United States $0.012B 0.00
Mangoceuticals (MGRX) United States $0.012B 0.00
Ernexa Therapeutics (ERNA) United States $0.011B 0.00
Phio Pharmaceuticals (PHIO) United States $0.010B 0.00
Talphera (TLPH) United States $0.010B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.010B 0.00
Traws Pharma (TRAW) United States $0.010B 0.00
SHINECO (SISI) China $0.009B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
Citius Pharmaceuticals (CTXR) United States $0.009B 0.00
Biomerica (BMRA) United States $0.008B 0.00
Nuvilex (PMCB) United States $0.007B 0.00
Carisma Therapeutics (CARM) United States $0.007B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.007B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.007B 0.00
Aptorum Group (APM) United Kingdom $0.006B 0.00
TransCode Therapeutics (RNAZ) United States $0.006B 0.00
Plus Therapeutics (PSTV) United States $0.006B 0.00
Klotho Neurosciences (KLTO) United States $0.006B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.005B 0.00
Indaptus Therapeutics (INDP) United States $0.005B 0.00
Incannex Healthcare (IXHL) Australia $0.005B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.005B 0.00
Xenetic Biosciences (XBIO) United States $0.005B 0.00
Alaunos Therapeutics (TCRT) United States $0.004B 0.00
Redhill Biopharma (RDHL) Israel $0.004B 0.00
PainReform (PRFX) Israel $0.004B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.004B 0.00
Jaguar Animal Health (JAGX) United States $0.004B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
Heatwurx (PCSA) United States $0.004B 0.00
InMed Pharmaceuticals (INM) Canada $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
CERo Therapeutics Holdings (CERO) United States $0.003B 0.00
Aditxt (ADTX) United States $0.003B 0.00
SciSparc (SPRC) Israel $0.003B 0.00
Qualigen Therapeutics (QLGN) United States $0.003B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.003B 0.00
TNF Pharmaceuticals (TNFA) United States $0.002B 0.00
Conduit Pharmaceuticals (CDT) United States $0.002B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
Universe Pharmaceuticals INC (UPC) China $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
MEI Pharma (MEIP) United States $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Silence Therapeutics (SLN) United Kingdom $0.000B 0.00